Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
This article was originally published in The Tan Sheet
Executive Summary
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
You may also be interested in...
Experts Address Chondroitin Testing In Wake Of ConsumerLab Report
Results of a recent ConsumerLab.com report on joint supplements that found 7 out of 11 tested products contained less chondroitin than stated on the label did not surprise experts in the industry
FDA public meeting
FDA will hold a public meeting Feb. 7 to discuss potential revisions of chemistry, manufacturing and controls supplement regulations, the agency announces Jan. 5. "FDA is evaluating how it could revise its regulations to allow for consideration of risk-based approaches based on manufacturing process understanding, including prior-knowledge of similar products, and overall quality systems to provide an enhanced risk-based approach to the regulatory process, which would reduce the number of supplements," FDA writes. The agency is "considering redefining what FDA considers to be a major manufacturing change, reducing the reporting burden for certain changes, and creating a new reporting category of manufacturing changes that would not require notification to FDA." The decision is in line with FDA's Pharmaceutical Current Good Manufacturing Practices for the 21st Century Initiative (1"The Tan Sheet" July 3, 2006, p. 6). Comments should be submitted March 7...
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei